458 related articles for article (PubMed ID: 34154602)
21. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
22. Comparison of single copy gene‑based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19‑directed CAR T cells in treated patients.
Schubert ML; Berger C; Kunz A; Schmitt A; Badbaran A; Neuber B; Zeschke S; Wang L; Riecken K; Hückelhoven-Krauss A; Müller I; Müller-Tidow C; Dreger P; Kröger N; Ayuk FA; Schmitt M; Fehse B
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35294040
[TBL] [Abstract][Full Text] [Related]
23. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma.
Oluwole OO; Jansen JP; Lin VW; Chan K; Keeping S; Navale L; Locke FL
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1581-1588. PubMed ID: 32561336
[TBL] [Abstract][Full Text] [Related]
24. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany.
Bethge WA; Martus P; Schmitt M; Holtick U; Subklewe M; von Tresckow B; Ayuk F; Wagner-Drouet EM; Wulf GG; Marks R; Penack O; Schnetzke U; Koenecke C; von Bonin M; Stelljes M; Glass B; Baldus CD; Vucinic V; Mougiakakos D; Topp M; Fante MA; Schroers R; Bayir L; Borchmann P; Buecklein V; Hasenkamp J; Hanoun C; Thomas S; Beelen DW; Lengerke C; Kroeger N; Dreger P
Blood; 2022 Jul; 140(4):349-358. PubMed ID: 35316325
[TBL] [Abstract][Full Text] [Related]
25. Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells.
Mika T; Maghnouj A; Klein-Scory S; Ladigan-Badura S; Baraniskin A; Thomson J; Hasenkamp J; Hahn SA; Wulf G; Schroers R
Front Mol Biosci; 2020; 7():84. PubMed ID: 32500079
[TBL] [Abstract][Full Text] [Related]
26. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
27. Clinically Applicable Assessment of Tisagenlecleucel CAR T Cell Treatment by Digital Droplet PCR for Copy Number Variant Assessment.
Gkazi SA; Gravett E; Bautista C; Bartram J; Ghorashian S; Adams SP
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886920
[TBL] [Abstract][Full Text] [Related]
28. Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups.
Bastos-Oreiro M; Gutierrez A; Reguera JL; Iacoboni G; López-Corral L; Terol MJ; Ortíz-Maldonado V; Sanz J; Guerra-Dominguez L; Bailen R; Mussetti A; Abrisqueta P; Hernani R; Luzardo H; Sancho JM; Delgado-Serrano J; Salar A; Grande C; Bento L; González de Villambrosía S; García-Belmonte D; Sureda A; Pérez-Martínez A; Barba P; Kwon M; Martín García-Sancho A
Front Immunol; 2022; 13():855730. PubMed ID: 35911769
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma.
Cortes-Bullich A; Perez A; Bachmeier C; Mhaskar R; Chavez JC; Shah B; Nishihori T; Khimani F; Lazaryan A; Davila ML; Locke FL; Jain MD
Transplant Cell Ther; 2021 Sep; 27(9):768.e1-768.e6. PubMed ID: 34077811
[TBL] [Abstract][Full Text] [Related]
30. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma.
Haradhvala NJ; Leick MB; Maurer K; Gohil SH; Larson RC; Yao N; Gallagher KME; Katsis K; Frigault MJ; Southard J; Li S; Kann MC; Silva H; Jan M; Rhrissorrakrai K; Utro F; Levovitz C; Jacobs RA; Slowik K; Danysh BP; Livak KJ; Parida L; Ferry J; Jacobson C; Wu CJ; Getz G; Maus MV
Nat Med; 2022 Sep; 28(9):1848-1859. PubMed ID: 36097221
[TBL] [Abstract][Full Text] [Related]
31. A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy.
Badaracco J; Gitlin M; Keating SJ
Transplant Cell Ther; 2023 Jan; 29(1):59.e1-59.e6. PubMed ID: 36272529
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
[TBL] [Abstract][Full Text] [Related]
33. Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Schubert ML; Dietrich S; Stilgenbauer S; Schmitt A; Pavel P; Kunz A; Bondong A; Wegner M; Stadtherr P; Jung S; Ho AD; Müller-Tidow C; Schmitt M; Dreger P
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1575-1580. PubMed ID: 32422254
[TBL] [Abstract][Full Text] [Related]
34. Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
Gagelmann N; Bishop M; Ayuk F; Bethge W; Glass B; Sureda A; Pasquini MC; Kröger N
Transplant Cell Ther; 2024 Jan; ():. PubMed ID: 38281590
[TBL] [Abstract][Full Text] [Related]
35. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma.
Locke FL; Filosto S; Chou J; Vardhanabhuti S; Perbost R; Dreger P; Hill BT; Lee C; Zinzani PL; Kröger N; López-Guillermo A; Greinix H; Zhang W; Tiwari G; Budka J; Marincola FM; To C; Mattie M; Schupp M; Cheng P; Bot A; Shen R; Bedognetti D; Miao H; Galon J
Nat Med; 2024 Feb; 30(2):507-518. PubMed ID: 38233586
[TBL] [Abstract][Full Text] [Related]
36. Digital polymerase chain reaction strategies for accurate and precise detection of vector copy number in chimeric antigen receptor T-cell products.
Murphy LA; Marians RC; Miller K; Brenton MD; Mallo RLV; Kohler ME; Fry TJ; Winters AC
Cytotherapy; 2023 Jan; 25(1):94-102. PubMed ID: 36253252
[TBL] [Abstract][Full Text] [Related]
37. [Cellular kinetics and outcome of tisagenlecleucel for diffuse large B-cell lymphoma].
Hanajiri R; Furukawa K; Nakashima M; Ushijima Y; Shimada K; Ishikawa Y; Terakura S; Murata M; Kiyoi H
Rinsho Ketsueki; 2023; 64(3):167-174. PubMed ID: 37019669
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma.
Dickinson M; Martinez-Lopez J; Jousseaume E; Yang H; Chai X; Xiang C; Wang T; Zhang J; Ramos R; Schuster SJ; Fowler N
Leuk Lymphoma; 2024 Mar; 65(3):323-332. PubMed ID: 38179688
[TBL] [Abstract][Full Text] [Related]
39. Application of droplet digital PCR for the detection of vector copy number in clinical CAR/TCR T cell products.
Lu A; Liu H; Shi R; Cai Y; Ma J; Shao L; Rong V; Gkitsas N; Lei H; Highfill SL; Panch S; Stroncek DF; Jin P
J Transl Med; 2020 May; 18(1):191. PubMed ID: 32384903
[TBL] [Abstract][Full Text] [Related]
40. Next-Generation Chimeric Antigen Receptor T-cells.
Yi D; Gergis M; Hsu J; Yang Y; Bi X; Aljurf M; Gergis U
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):117-121. PubMed ID: 36537905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
